SCHEMBL23218710

SCHEMBL23218710

CC(C)n1nc(COc2cccc(CC(=O)O)c2)c2cc(-c3cccc(CN)c3)ccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 3/20 0.50
PLAU P00749 4/20 0.42
PLG P00747 2/20 0.42
F11 P03951 2/20 0.42
TPSB2 P20231 2/20 0.42
KLKB1 P03952 1/20 0.42
F7 P08709 1/20 0.42
CMKLR1 Q99788 1/20 0.40
ICMT O60725 2/20 0.39
SSTR5 P35346 1/20 0.38
FFAR1 O14842 2/20 0.38
NR1H4 Q96RI1 1/20 0.37
FGFR2 P21802 1/20 0.37
FGFR3 P22607 1/20 0.37
NR4A2 P43354 1/20 0.36
POLB P06746 1/20 0.36
PPARG P37231 1/20 0.36
NR1H2 P55055 1/20 0.36
PPARD Q03181 1/20 0.36
PPARA Q07869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23218903 0.91 CFD (0.42) CFDPLAUPLGF11TPSB2
SCHEMBL23219181 0.89 NR4A2 (0.50) CFDPLAUSSTR5NR1H4NR4A2
SCHEMBL29591762 0.89 NR4A2 (0.50) CFDPLAUSSTR5NR1H4NR4A2
SCHEMBL29852680 0.86 LOXL2 (0.46) CFDPLAUSSTR5NR1H4NR4A2
SCHEMBL29593174 0.86 CFD (0.62) CFDPLAUPLGF11TPSB2
SCHEMBL23218806 0.86 LOXL2 (0.46) CFDPLAUSSTR5NR1H4NR4A2
SCHEMBL23219211 0.86 CFD (0.62) CFDPLAUPLGF11TPSB2
SCHEMBL29592507 0.84 CFD (0.46) CFDPLAUPLGF11TPSB2
SCHEMBL23218914 0.84 CFD (0.46) CFDPLAUPLGF11TPSB2
SCHEMBL23219043 0.84 CFD (0.48) CFDPLAUPLGF11TPSB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885PLAU 1119/4885PLG 421/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885PLAU 144/4885PLG 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.